Free Cash Flow

Agfa-Gevaert posts strong Q4 results, but a full-year profit dip reveals a company in deep transformation, betting on digital health and green energy.

A new report shows Munich and Hamburg are outpacing rivals in attracting investment, leveraging online credibility as a powerful new tool on the global stage.

As a $150M expansion nears completion, Louisiana's largest casino bets on a 20-year veteran to steer its financial future and tribal economic goals.

The deepwater oil and gas producer launches a major stock offering to strengthen its balance sheet, causing share dilution but aiming for long-term stability.

With $128.7M in cash and zero debt, Singapore's OMS Energy is leveraging its financial might and a key Saudi Aramco deal to dominate the oilfield market.

Kodiak AI now has 20 driverless trucks on the road, an industry first. But with mounting losses, can its tech innovation outpace its high cash burn?

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

The engineering giant saw strong revenue growth in 2025, fueled by its nuclear focus, but one-off costs and investment writedowns hit its bottom line.

A new pilot in South Africa will test foldable shipping containers that could slash costs, cut emissions, and revolutionize the global freight industry.

The industrial giant earns top global ESG ratings for the third straight year, proving that strategic sustainability drives both environmental impact and investor value.

Easterly Asset Management's deal to absorb Olstein's funds marks a key industry consolidation, promising lower fees and a unified value investing powerhouse.

At CERAWeek 2026, energy infrastructure leader Williams will outline its strategy for leveraging natural gas to power the AI and data center boom.

Rainforest Distribution is betting on a unified, AI-powered platform from Manhattan Associates to navigate the volatile food and beverage landscape.

Employer confidence is back to 2022 levels, but a new survey reveals AI's uneven impact and hiring plans were made before new geopolitical tensions.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

The insurer posted strong 2025 results, with core underwriting gains and niche market growth overshadowing a $15.7 million hit from California fires.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

DuPont honors veterans at THE PLAYERS Championship while showcasing how its battlefield-proven materials are now revolutionizing high-performance golf equipment.

A new survey finds companies are dynamically adjusting investment hurdles in response to market chaos, leveraging technology to navigate an uncertain world.